US based VolitionRx Limited has announced that it has added to its extensive clinical trial programme with the execution of a contract under the previously announced Memorandum of Understanding, to conduct its first large-scale lung cancer study in conjunction with the prestigious National Taiwan University (NTU).

The study will be conducted under the supervision of Professor Chen Jin-Shing in the Department of Surgery of NTU and will include 1,200 subjects receiving Low-Dose Computed Tomography scans, including 1,000 with lung cancer.

Volition recently announced preliminary results from two proof of concept studies utilising its first optimized product-grade assay:

• In a lung cancer cohort (76 subjects), a single Nu.Q™ assay detected lung cancer, including stage I lung cancer. The Area Under the Curve ("AUC") for this single assay was 85%, cancer versus healthy.
• In a second confirmatory lung cancer cohort (152 subjects), the same single Nu.Q™ assay also detected lung cancer with an AUC of 79%, cancer versus healthy.

Volition has also recently executed a nonbinding Memorandum of Understanding with Shanghai Fosun Long March Medical Science Co., Ltd. with the shared intention to enter into a binding agreement and to conduct three small-scale clinical trials in China. One of the trials is in lung cancer, and the others are in colorectal cancer and ovarian cancer, with preliminary data expected in 2019.